Regulatory Filings and Regulatory Approvals. Before making any submission to any Regulatory Authority, the Sponsor Party shall consult with and provide the other Party the opportunity to review draft Regulatory Filings with respect to a Joint Global Study (e.g., Type B meeting packages, key documents in INDs, NDAs, fast track, breakthrough designation and orphan drug application) to be submitted to the Regulatory Agency in its Sponsored Territory in advance of submission. Such other Party shall provide any comments within [***] ([***]) Business Days after receipt, but such Sponsor Party shall not be required to delay any planned submissions if it does not receive timely comments from such other Party. As between the Parties, A▇▇▇▇▇▇▇ shall prepare the first draft of the global submission dossier for the Parties’ review and comments.
Appears in 3 contracts
Sources: Joint Clinical Collaboration Agreement (ArriVent Biopharma, Inc.), Joint Clinical Collaboration Agreement (ArriVent Biopharma, Inc.), Joint Clinical Collaboration Agreement (ArriVent Biopharma, Inc.)